# Study to Assess SLN124 in Patients With Polycythemia Vera

Source: https://onco.cc/trials/nct05499013/  
OnCo record `nct05499013` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SLN124 in myeloproliferative neoplasms, run by Silence Therapeutics plc, active and no longer recruiting.

## Summary

Study to Assess SLN124 in Patients With Polycythemia Vera is a phase 1/2 interventional study registered as NCT05499013 by Silence Therapeutics plc, with 69 participants enrolled, started 2023-01-26 and due to reach its primary completion in 2026-09. Interventions recorded: SLN124 and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05499013
- Phase: 1/2
- Setting: Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera
- Sponsor: Silence Therapeutics plc
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT05499013: https://clinicaltrials.gov/study/NCT05499013

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)

---
JSON: https://onco.cc/api/v1/entities/nct05499013.json